PD-1/PD-L1 inhibitor plus chemotherapy improves overall survival in advanced gastric and esophageal junction cancer
PD-1 Inhibitors Plus Chemotherapy Improve Survival in Gastric Cancer
This meta-analysis of 6,517 patients found that PD-1/PD-L1 inhibitor plus chemotherapy significantly improved overall survival (HR, 0.79) an…
Combining PD-1 or PD-L1 inhibitors with chemotherapy shows improved survival and response rates for patients with advanced gastric or esopha…
Perioperative immune checkpoint inhibitors with chemotherapy increase pathological complete response rate by 2.91 RR
Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Cancer Response
This meta-analysis of randomized controlled trials evaluated perioperative immune checkpoint inhibitors combined with chemotherapy for resec…
Adding immune checkpoint inhibitors to chemotherapy may significantly improve response rates for patients with certain types of stomach and …
Pembrolizumab plus chemotherapy improves ORR and OS in HER2-negative advanced gastric or gastroesophageal junction cancer
Pembrolizumab Plus Chemotherapy Improves Outcomes for Advanced Gastric Cancer
This systematic review and meta-analysis of 3406 patients found that pembrolizumab combined with chemotherapy significantly improved objecti…
Adding the drug pembrolizumab to chemotherapy shows promise in improving survival and response rates for patients with advanced gastric canc…
Zolbetuximab combined with chemotherapy improves progression-free survival and overall survival in CLDN18.2-expressing gastric cancers
New drug shows promise for advanced stomach and esophageal cancer
This systematic review evaluates zolbetuximab in combination with chemotherapy for patients with advanced G/GEJ adenocarcinoma expressing hi…
A new treatment called zolbetuximab may improve survival rates for patients with specific types of advanced stomach and esophageal cancers.